The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and prognosis of DDX41- and GATA2-mutated myeloid neoplasms.
 
Ahmad Nanaa
No Relationships to Disclose
 
Hassan B. Alkhateeb
No Relationships to Disclose
 
Talha Badar
No Relationships to Disclose
 
James M. Foran
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Novartis; SERVIER; Syros Pharmaceuticals; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Actinium Pharmaceuticals (Inst); Aptose Biosciences (Inst); H3 Biomedicine (Inst); Kura Oncology (Inst); Sellas Life Sciences (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Lisa Ostrosky Sproat
No Relationships to Disclose
 
Cecilia Ysabel Arana Yi
No Relationships to Disclose
 
Phuong L. Nguyen
No Relationships to Disclose
 
Dragan Jevremovic
Speakers' Bureau - Abbvie
 
Patricia T. Greipp
No Relationships to Disclose
 
Naseema Gangat
No Relationships to Disclose
 
Ayalew Tefferi
No Relationships to Disclose
 
Mark Robert Litzow
Consulting or Advisory Role - Jazz Pharmaceuticals; Omeros
Research Funding - Abbvie; Abbvie/Genentech; Actinium Pharmaceuticals; Amgen; Astellas Pharma; Pluristem Therapeutics; Tolero Pharmaceuticals
Other Relationship - Biosight
 
Mithun Vinod Shah
Research Funding - Archer
 
Abhishek Avinash Mangaonkar
Research Funding - BMS (Inst)
 
Mrinal Patnaik
No Relationships to Disclose
 
David Viswanatha
No Relationships to Disclose
 
Rong He
No Relationships to Disclose
 
Aref Al-Kali
Research Funding - Ambit BioSciences (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); H3 Biomedicine (Inst); MedImmune (Inst); Novartis (Inst); Onconova Therapeutics (Inst)